

NUVECTRA®

November 12, 2019

Dear Physician Partner,

I am reaching out to provide an important update regarding Nuvectra. Today, Nuvectra voluntarily filed for reorganization under Chapter 11 of the United States Bankruptcy Code.

Below are the most important points you need to know:

- **Nuvectra is committed to supporting existing patients using Algovita®, as well as the physicians, clinicians and facilities treating them.**
- **The safety and functionality of Algovita will not be impacted by the court-supervised process.**
- **We are maintaining a team of clinical specialists and product support specialists who are available to answer questions and help maintain devices.**
- **We expect to continue to honor warranty claims for existing patients using Algovita.**
- **The Company is currently suspending its support of future implants until the Company's path forward is determined and recommends that you cease any new implantations, as well as trial procedures and clinical studies in progress, until that time.**

We are committed to keeping patients and physicians informed throughout this process as there are pertinent updates to share. Below is a set of Frequently Asked Questions with additional information about the announcement.

We appreciate everything that you do to help improve the lives of patients.

Thank you for your continued support.

Sincerely,

A handwritten signature in blue ink that reads "Fred B Parks". The signature is fluid and cursive, with the first name "Fred" and last name "Parks" clearly legible.

Fred Parks
Chief Executive Officer

Physician FAQ

1. What was announced?

- On November 12, 2019, Nuvectra elected to file a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of Texas.
- The Company intends to use this court-supervised process to continue its review of a range of options to maximize value and address its financial obligations.
- The Board of Directors and management team continue to believe that the Company and its assets have considerable value and are exploring a range of options including, a sale of the Company as a whole, of the Algovita, of Virtis® or of specified assets.

2. What is Chapter 11?

- Chapter 11 is a section of the U.S. Bankruptcy Code that allows companies to implement reorganizations through an in-court proceeding while continuing to operate their businesses.

3. Why is Nuvectra filing for Chapter 11?

- Since launching as an independent company, Nuvectra has been investing in our mission to help physicians improve the lives of people with chronic conditions.
- We were successful in bringing Algovita to market and have opportunities in our pipeline, including Virtis, which we believe will generate value in the future.
- To fund our innovation and commercialization efforts, the Company took on substantial debt.
- We have been working to achieve an alternative path forward through our extensive review of options for our business over the past several months.
- Following constructive discussions with our lenders, the court-supervised process we are starting today will provide us the time and flexibility we need to continue our review of options, maximize the value of our assets and address our financial obligations.

4. Is Nuvectra going out of business because of the Chapter 11 filing? What does this mean for operations?

- Nuvectra is committed to supporting existing patients using Algovita, as well as the physicians, clinicians and facilities treating patients with Algovita.
- The safety and functionality of Algovita will not be impacted by the court-supervised process.
- The Company is currently suspending its support of future implants until our path forward is determined, and we recommend physicians cease any new implantations, as well as trial procedures and clinical studies in progress, until that time.

5. Does Nuvectra have sufficient liquidity to meet its business obligations?

- We believe we have sufficient liquidity to meet our post-petition business obligations.

6. When does Nuvectra expect to complete the Chapter 11 process?

- While we will move through this process as efficiently as possible, there is no definitive timeline to share.
- We will continue to keep stakeholders informed as there are updates to share.

7. How will the restructuring affect patients with Algovita?

- We are committed to supporting the existing patients who are using our device and their physicians, clinicians and facilities by maintaining a team of clinical specialists and product support specialists.
- The safety and functionality of Algovita for current patients will not be impacted by the court-supervised process.

8. How does this affect physicians?

- Nuvectra is committed to supporting existing patients using Algovita, as well as the physicians, clinicians and facilities treating patients with Algovita.
- The safety and functionality of Algovita for current patients will not be impacted by the court-supervised process.
- That being said, we are currently suspending our support of future implants until our path forward is determined, and we recommend physicians cease any new implantations, as well as trial procedures and clinical studies in progress, until that time.

9. Will Nuvectra be able to continue servicing my patients' devices?

- We are committed to supporting the existing patients who are using our device and their physicians, clinicians and facilities by maintaining a team of clinical specialists and product support specialists.
- The safety and functionality of Algovita for current patients will not be impacted by the court-supervised process.

10. Should I be concerned about the safety of my patients with Algovita?

- No. The safety and functionality of Algovita for current patients will not be impacted by the court-supervised process.
- We are committed to supporting the patients who are using our device and their physicians and clinicians by maintaining a team of clinical specialists and product support specialists.

11. Why are you recommending that physicians withhold from prescribing and proceeding with implantations?

- We are currently suspending our support of future implants until the Company's path forward is determined and we are therefore recommending that physicians cease any new implantations, as well as trial procedures and clinical studies in progress, until that time.

12. What about trials and clinical studies in progress?

- We are recommending that physicians cease any new implantations, as well as trial procedures and clinical studies in progress, until the Company's path forward is determined.

13. How can I obtain more information?

- If you have any questions regarding your Algovita device, please don't hesitate to contact your physician or Nuvectra by calling 1-844-727-7897 (or +1-214-618-4980 for calls originating outside the U.S.) and selecting option "1" or sending an email to support@nuvectramed.com.